Adiponectin Reduces Atherosclerosis in Apolipoprotein E-Deficient Mice

By Y. Okamoto, S. Kihara, N. Ouchi, M. Nishida, Y. Arita, M. Kumada, K. Ohashi, N. Sakai, I. Shimomura, Hideki Kobayashi and 4 more. Circulation, 2002

1,066 citations recorded by the source corpus.

Subfields: Emergency Medicine, Epidemiology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/afd54f2df4a9cb813108979e37858e9ac90f9f5a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

In Pulmonary and Respiratory Medicine

Citations in the corpus

Adipokines Mediate Inflammation and Insulin Resistance (2013, background): “Thus adiponectin can also suppresses the development of atherosclerosis, fatty liver diseases, and liver fibrosis (Okamoto et al., 2002; Xu et al., 2003).”
Adipocytokines in Obesity and Metabolic Disease (2014, positive): “…activity and its downstream adhesion molecules Published by Bioscientifica Ltd Downloaded from Bioscientifica.com at 06/18/2023 02:10:14AM via free access Jo u rn a l o f E n d o cr in o lo g y leading to reduced monocyte adhesion to endothelial cells (Ouchi et al. 1999, Okamoto et al. 2002).”
Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. (2003, background): “E–deficient mice, infection of adenovirus-expressing human adiponectin ameliorates atherosclerosis (25).”
Increased oxidative stress in obesity: implications for metabolic syndrome, diabetes, hypertension, dyslipidemia, atherosclerosis, and cancer. (2013, background): “diponectin, which has insulin-sensitizing [31—33] nd antiatherogenic effects [34,35], is decreased in he circulation in obesity [36]; this indicates that ecreased levels of circulating adiponectin may ontribute to insulin resistance and atherosclerosis n obese individuals.”
Adiponectin, a Therapeutic Target for Obesity, Diabetes, and Endothelial Dysfunction (2017, background): “Basic scientific studies have demonstrated that adiponectin has insulin-sensitizing [5], anti-atherogenic, and anti-inflammatory properties [6,7].”
Obesity, Metabolic Syndrome, and Cardiovascular Disease (2007, background): “Endothelial function is impaired in adiponectin knock-out mice, whereas forced adiponectin expression reduces atherosclerotic lesions in a mouse model of atherosclerosis (39).”
Adipose tissue-derived factors: impact on health and disease. (2006, positive): “creases in atherosclerotic lesion formation (140, 141).”
Adiponectin: A novel adipokine linking adipocytes and vascular function. (2004, positive): “Adiponectin associated with foam cells in the fatty streak lesions, suppressed the expression of vascular cell adhesion mole- cule-1 (VCAM-1) and class A scavenger receptors, and tended to reduce levels of TNF␣ (31).”
Adiponectin Regulation and Function (2018, positive): “In apolipoprotein E-deficient mice (ApoE-KO), a model of atherosclerosis, adiponectin administration decreases vascular inflammation, lesion formation and atherosclerosis development (228).”